Immunogenicity of biosimilars

• At: Basel (Switzerland) (2008)
• Type: Presentation
• By: JISKOOT, Wim (LACDR, Leiden University, Leiden, Netherlands)
• Co-author(s): Schellekens, Huub (Utrecht University, Utrecht, Netherlands)
  
• Abstract:

  Since the introduction of hybridoma and recombinant DNA technologies more than 30 years ago, more than 150 proteins have entered the clinic as hormones, growth factors, immune-modulating agents and monoclonal antibodies. Moreover, hundreds of biopharmaceuticals are in the pipeline. These products are life-saving and/or increase the quality of

  ..

The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login